



Supplementary Fig. 1. Flow chart of the study.

**Supplementary Table 1.** Characteristics of individual patients with COVID-19

No	Total duration of admission (day)	Time to evaluation after admission (day)	Past psychiatric history	Prescribe psychotropic medication	HADS-A		HADS-D		ISI		BDI item 9	
					Baseline	Last follow-up	Baseline	Last follow-up	Baseline	Last follow-up	Baseline	Last follow-up
1	36	2	None	Mirtazapine 15 mg, Quetiapine 25 mg, Clonazepam 0.5 mg Mirtazapine 7.5 mg	17	8	18	6	18	5	2	0
2	12	3	None		6	6	6	4	9	11	0	0
3	24	11	None		5	0	4	0	1	0	0	0
4	21	3	None		1	2	3	3	0	4	0	0
5	21	3	None		3	2	12	4	5	0	0	0
6	21	3	None		6	6	9	10	10	9	0	0
7	21	5	Insomnia		7	8	10	11	8	6	0	0
8	19	3	Insomnia		2	12	12	14	14	20	1	0
9	13	4	Depression		6	8	12	12	0	15	1	0
10	16	5	None		2	0	2	1	2	2	0	0
11	18	3	None		7	11	5	7	12	13	0	0
12	18	3	None		8	6	4	5	12	5	0	0
13	11	3	None	Mirtazapine 7.5 mg	8	6	18	16	3	4	0	0
14	17	3	None		6	0	2	0	2	0	0	0
15	13	3	None		4	3	5	2	2	1	0	0
16	11	1	None		6	8	9	7	6	2	0	0
17	17	6	None	Lorazepam 0.5 mg	7	5	7	4	2	1	0	0
18	15	5	None	Lorazepam 0.5 mg	9	8	7	10	0	6	0	0
19	12	3	None		2	1	1	1	1	0	0	0
20	12	4	None		1	2	3	4	5	1	0	0
21	13	3	None		11	7	7	7	6	0	0	0
22	9	3	None	Escitalopram 7.5 mg	13	11	13	15	2	0	0	0
23	15	2	None	Mirtazapine 7.5 mg	4	1	16	9	1	3	0	0
24	14	4	None		7	7	7	8	9	10	0	0
25	34	3	None	Trazodone 25 mg	0	0	0	0	0	0	0	0
26	27	6	None	Escitalopram 5 mg, alprazolam 0.25 mg	0	0	3	0	4	2	0	0
27	24	3	Panic disorder		6	2	2	4	0	0	0	0
28	28	3	None		3	2	3	4	0	1	0	0
29	31	17	None		4	3	2	5	0	6	0	0
30	29	3	None		3	3	3	4	5	6	0	0
31	31	4	None		4	1	2	2	9	1	0	0
32	25	4	None		1	0	2	0	8	2	0	0
33	19	5	None		5	0	8	4	5	0	0	0

HADS-A, Hospital Anxiety and Depression Scale-anxiety subscale; HADS-D, Hospital Anxiety and Depression Scale-depression subscale; ISI, Insomnia Severity Index; BDI, Beck Depression Inventory.